Kornimate/medical-research-clean huggingface dataset:
urodynamic changes following bladder injury

Conditions: Urologic Injuries; Urodynamic Changes; Bladder Dysfunction

Summary: this study is a unique one as it si done for first time to all patients following bladder injury in pas surgery. bladder function will be assessed by urodynamic study.

patients will be initially assessed by overactive bladder (oab) and incontinence questionnaire. examination was done to determine any neurological, or congenital abnormalities. urodynamic study (uds) will done for all patients. the patients will be asked to drink fluids to obtain a comfortably full bladder. initially, a pelvic-abdominal ultrasound was done followed by the uds. urodynamic study consisted of uroflowmetry (volume: ≥150 ml and qmax: 20-30 ml/s); filling cystometry in physiological or medium filling rate of 40 ml/min (using normal saline at room temperature through a double lumen urethral catheter); stress leak test; and pressure flow study. no sedation will be administered during the study as the patient should be aware. the patients were placed in a semi-seated lithotomy position. after a detailed explanation to the patient, the examination will begin by passing a catheter into the bladder (5 fr) to measure the postvoiding residual urine followed by filling the bladder and measuring the intravesical pressure through the catheter. a rectal catheter was placed for measuring the abdominal pressure. the systems will be always zeroed at the atmospheric pressure. the patients will be periodically asked to cough to check the operation of the equipment and instructed to report her sensations. the volume of the first sensation of filling, first desire (1 s) and second desire (2 s) were recorded. when the bladder was filled up to 150 ml, patients were asked to cough (valsalva) to predict the stress leakage. if not occur at 150 ml, the bladder was refilled, and the stress test was repeated until the leakage occurred or the bladder capacity was reached. additionally, any unidentified involuntary detrusor contractions will be noted. when the patient had the urge to void, the permission for voiding will be given. then voiding cystometrogram (pressure-flow) was performed and the urodynamic parameters, such as maximum flow rate (qmax) and detrusor pressure at maximum flow (pdet qmax) will be observed.

Eligibility criteria:
inclusion criteria: * age 20-40 years * placenta accreta managed either by cesarean hysterectomy or by uterine sparing conservative treatment * bladder injury was diagnosed and repaired during surgery 6 months ago. exclusion criteria: * patients with neurological problems * presence of congenital urinary system anomalies * urinary tract infections (utis) * previous urologic surgeries * patients with stone bladder or tumour * diabetic patients
investigating eye-movement biomarkers of disease severity and cognition in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: the overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in multiple sclerosis (ms) patients to further build up a database of ms patients and train a machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of ms disease severity and cognitive status.

this study will use a single group design in a cohort of ms patients. eligible patients with ms will be selected and categorized based on their expanded disability status scale (edss) score. patients eye movements will be captured using the patented eye-tracking technology at one single time point. in addition to the eye-tracking tests, patient phenotypes will be further detailed via brief functional and cognitive assessments using the edss, brief international cognitive assessment for ms (bicams) and multiple sclerosis functional composite (msfc). all patients will be required to participate in a single session.

Eligibility criteria:
inclusion criteria: * able to provide informed consent. * aged 18 years or older at the time of enrollment. * able to read in either french or english. * visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc. are permitted) * confirmed diagnosis of ms with no signs of progressive increase in physical disability within the past six months. * neurological condition is medically stable during the study visit. exclusion criteria: * evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control. * presence of comorbid neurological conditions to avoid eye movement anomaly confounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia). * diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments. * recent (less than three months from enrollment) start of, change of dose, or irregular use of, new prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics and anticonvulsants. occasional use of benzodiazepines for medical procedures is permitted, at the investigator's discretion, but should not occur within a short time period prior to or during an eye movement assessment * diagnosis of clinically isolated syndrome (cis), radiologically isolated syndrome (ris) or primary progressive ms (ppms). * patients who are currently experiencing a relapse or who have experienced a relapse within the last three months. a relapse is defined as appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. the abnormality must have been present for at least 24 hours and occurred in the absence of fever (\< 37.5°c) or known infection. * patients who have been undergoing disease-modifying therapy for less than three months
a dose-escalation study in subjects with advanced malignancies

Conditions: Solid Tumor; Advanced Cancer; Metastatic Cancer

Summary: this is an open label, dose escalation study using a 3 + 3 design to determine if incb028060 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. doses will be escalated unless a dose-limiting toxicity (dlt) is observed in one of three subjects.


Eligibility criteria:
inclusion criteria: * subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available * subjects with life expectancy of 12 weeks or longer. * subjects with eastern cooperative oncology group (ecog) performance status of 0, 1 or 2. exclusion criteria: * subjects who received any anti-cancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycin-c or nitrosoureas. * subjects with history of brain metastases or spinal cord compression. * subjects who have undergone a bone marrow or solid organ transplant. * subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment. * subjects with clinically significant non-healing or healing wounds or subjects with lung tumor lesions with increased likelihood of bleeding * subjects with a history of any gastrointestinal condition

Keywords: refractory, advanced malignancies
glycans bound to serum haptoglobin: a novel gastric cancer tumor biomarker

Conditions: Gastric Cancer

Summary: the purpose of this study is to evaluate sensitivity and specificity of newly defined tumor biomarker with gastric cancer pts and cancer-free healthy volunteers.

measurements of specific glycosylation changes in serum haptoglobin.

Eligibility criteria:
arm1 (gastric cancer patient) 1. inclusion criteria: * male or female over 19 years * patients with histologically gastric cancer (included gastroesphageal junction) * primary gastric cancer or/and metastatic gastric cancer. * understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted 2. exclusion criteria: * prior or present history of malignancies other than gastric cancer * any condition that confounds the ability to interpret data from the study under the investigational confirmed. arm2 (cancer-free healthy volunteers) 1. inclusion criteria: * male or female over 19 years * cancer-free status. * understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted 2. exclusion criteria: * prior or present history of malignancies (included gastric cancer) * any condition that confounds the ability to interpret data from the study under the investigational confirmed
supported employment covid-19 rapid testing for pwid

Conditions: Health Behavior

Summary: this community-engaged project aims to improve the accessibility of rapid tests through a supported employment program for people who inject drugs (pwid). the program is called peer connect2test (peerc2t). pwid will be recruited by a community partner who provides syringe exchange services. pwid will the trained by the community partner to become peer health workers (phw) to distribute sars-cov-2 rapid tests to other pwid. investigators expect that peerc2t will improve knowledge, self-efficacy, and health behaviors among phw (aim 1). the study will use the re-aim framework in aims 2 and 3 to evaluate whether peerc2t improves sars-cov-2 testing uptake among other pwid (re; aim 2), and identify intervention considerations (aim; aim 3). the overall goal of this project is develop a transformative community-driven intervention in partnership with a community partner to promote widespread access to rapid testing among pwid.


Eligibility criteria:
inclusion criteria: * age 18 and older, understand english exclusion criteria: -
computer-assisted adherence program for patients taking anti-hiv drugs

Conditions: Acquired Immunodeficiency Syndrome; HIV Infections

Summary: the purpose of this study is to evaluate the effectiveness of a computer-assisted, self-administered adherence program for patients on complicated anti-hiv drug regimens.

highly active antiretroviral therapy (haart) for hiv produces dramatic reductions in morbidity and mortality for many patients who maintain a high level of adherence to their medications. however, 20% to 33% of hiv infected patients will miss at least one of their medication doses over a one to three day period. patient self-report is the most practical method for assessing adherence, but it may produce unreliable and invalid results unless optimally performed. a computer-assisted, self-administered adherence program could improve hiv infected patients' adherence behaviors by accurately and efficiently assessing their medication adherence, delivering an adherence intervention to patients, and producing adherence reports for providers. by providing a neutral and seemingly private interview, computer programs may increase patient disclosure of non-adherence. this study will evaluate the efficacy of a computer-assisted, self-administered adherence program in reducing regimen misunderstandings and enhancing patient adherence. participants in this study will be recruited from within the positive health program at san francisco general hospital. patients will be randomly assigned to a control or intervention group. control group participants will complete an audio computer-assisted self-interview (a-casi) assessing their understanding of their medication regimen and adherence. intervention group participants will complete the adherence a-casi and will receive a brief computer-delivered intervention consisting of a graphical depiction of their correct regimen and strategies for improving adherence. study investigators will forward a computer-generated adherence report, which summarizes their adherence and suggests appropriate interventions, to the intervention group's health care providers. all participants will be assessed at least three times over a 6-month period: study entry, month 3, and month 6.

Eligibility criteria:
inclusion criteria * receiving hiv care at san francisco general hospital's positive health program * three or more antiretroviral medications * hiv-1 viral load \> 500 copies/ml * at least one previous salvage regimen * ability to read english at 8th grade level exclusion criteria * visual impairments that prevent patient from reading text on a computer screen * obvious cognitive impairment

Keywords: compliance medication antiretroviral adherence intervention treatment experienced
a comparison of post-sternotomy dressings

Conditions: Impaired Wound Healing; Postoperative Wound Infection-deep

Summary: the purpose of this study was to determine which of three types of dressings, a dry sterile dressing, a metallic silver dressing or an ionic silver dressing provided better patient outcomes for the post-sternotomy cardiac surgery patient population. in this prospective, randomized controlled trial, the hypothesis was that subjects who received either of the silver impregnated dressings would have better outcomes (better wound healing, less discomfort, and less incidence of infection). investigators also evaluated dressing factors such as adherence, time for application and ease of use.

no other information included.

Eligibility criteria:
inclusion criteria: * adult (at least 21 years of age) inpatients awaiting cardiac surgery or outpatients seen in the pre-surgical testing area prior to admission for surgery * having surgery at the study setting * english-speaking * able to understand and give consent * had the approval of their cardiothoracic surgeon to participate * had no known sensitivity to silver * had no known sensitivity to alginates exclusion criteria: * known sensitivity to silver * known sensitivity to alginates

Keywords: sternotomy incision silver dressing sternal wound infection
a clinical prospective study to validate a risk scoring model for the hmgc after curative surgery

Conditions: Predictive Cancer Model; Hepatic Metastasis; Gastric Cancer

Summary: a previous study of investigators established a risk scoring model for the occurrence of postoperative hepatic metastases in patients who underwent curative gastrectomy directly without neoadjuvant therapy. in order to further validate the clinical applicability of abovementioned model, investigators designed this prospective study, which also included patients who received neoadjuvant therapy before surgery, with the aim of exploring the applicability of the risk scoring model to this group of patients.

the study was a single-centre, prospective study. prospectively collected data were used to analyze the consistency between the actual outcomes of patients with or without hepatic metastases after curative gastrectomy and the predicted outcomes of the risk scoring model, in order to assess the clinical applicability of the model. in addition, analyses were performed to compare the differences in the risk of hepatic metastasis and the time interval of occurrence between patients who did not receive neoadjuvant therapy and those who received neoadjuvant therapy, as well as between patients with different outcomes after receiving neoadjuvant therapy (trg 0-1 vs. trg 2-3 in postoperative pathology).

Eligibility criteria:
inclusion criteria: 1. received curative gastrectomy (d2 lymph node dissection); 2. gastric cancer without distant organ metastasis, distant lymph node metastasis and peritoneal implantation (m0) confirmed by postoperative pathology; 3. no hepatic tumors and other occupying diseases, no chronic diseases such as cirrhosis and hepatitis, no hepatic schistosomiasis, no hepatic echinococcosis, no hepatic tuberculosis, and no severe fatty liver disease before the curative surgery; 4. no history of intraperitoneal chemotherapy; 5. no other serious concomitant diseases with satisfactory organ function; 6. no history of other malignant tumors; 7. comply with the protocol during the whole study period; 8. sign informed consent and permission of withdraw in the whole study period; 9. estimation the overall survival after surgery no less than 12 months; 10. consent to analysis of clinicopathological data and prognostic follow up; 11. karnofsky performance scores (kps) more than 60. exclusion criteria: 1. special histological types of gastric cancer (neuroendocrine, squamous, squamous cell, hepatoid adenocarcinoma or others); 2. gastro-esophageal junction cancer; 3. severe congestive heart failure, frequent arrhythmia, or myocardial infarction within 12 months; 4. immunosuppressive therapists for organ transplantation; 5. seriously uncontrolled recurrent infection; 6. history of other malignancies; 7. no abilities of self-knowledge or mental disorders; 8. combination of other serious diseases; 9. concurrent participation in other clinical trials.
primary immunodeficiencies and obstetrical neuraxial anaesthesia

Conditions: Infectious Complications (Epidural Abscess or Meningitis); Obstetrical Neuraxial Anaesthesia

Summary: the purpose of this study is to evaluate if neuraxial anesthesia (epidural or intradural anesthesia) used during childbirth is associated with more frequent infectious complications in patients with primary immunodeficiencies (pid).

neuraxial anaesthesia (epidural or intradural) is often used to alleviate pain during labour and childbirth. although extremely efficient and safe, rare but serious infectious complications such as epidural abscess or meningitis can occur afterwards. patients with pid tend to have a greater risk of infectious complications than the general population. with the progress of medical care in those pathologies, female patients are now giving birth more often. the use of neuraxial anaesthesia and the associated infectious complications have never been studied in this population. the investigators intend to review the medical records of pid patients who gave birth in an aphp hospital in the last 10 years to evaluate the use of neuraxial anesthesia and the frequency of infectious complications associated with neuraxial anesthesia.

Eligibility criteria:
inclusion criteria: * female patient included in the ceredih national register * aged \> 18 years exclusion criteria: * refuse to participate * deceased * minor * under judicial protection * obstetric file not available

Keywords: primary immunodeficiencies neuraxial anaesthesia obstetrical anaesthesia epidural abscess meningitis
comparison between surgical and conservative treatment for lumbar stenosis

Conditions: Lumbar Spinal Stenosis

Summary: this study aims to compare the outcomes of surgical treatment and conservative treatment at medium- and long-term period (minimum 2 years) in patients with lumbar stenosis who come to the observation of the pi's team at the rizzoli orthopaedic institute, through a series exhaustive questionnaires to self-administer to patients in order to define a path of "decision-making" as effective as possible for the patient and the doctor.

non-surgical treatment: conservative treatment may include different approaches, such as analgesics, anti-inflammatories, muscle relaxants, physical therapy, global postural rehabilitation, magnetic therapy, laser therapy, tens, massage, cognitive-behavioral therapy and all those procedures that can bring benefit in back and legs pain. surgical treatment: surgical treatment of lumbar stenosis is the decompression surgery which relieves the nerve structures to prevent permanent neurological damage. decompression can be made on one or more segments of the spine and can be done with laminectomy, hemilaminectomy, laminotomy. during a laminotomy part of the vertebral lamina is removed above and below the compressed nerve. the opening created is sometimes enough to relieve the compression on the nerve. in most cases, also the disc material and bone spur that compress the nerve are removed. during a laminectomy the vertebral lamina is completely removed, along with the disc and the bone material that compress the nerves. the opening produced by the removal of the lamina is protected by back muscles and ligaments. if the damage has occurred at several levels and bone of the vertebral support structures must be removed to achieve decompression, it can be performed a stabilization surgery with vertebral bone fusion (arthrodesis) in order to avoid instability of the column. fusion is carried out to eliminate the mobility between different vertebrae and it is achieved using bone derived from the patient's iliac crest or from a donor. the bone gradually grows and melts with the same vertebrae. this limits the movements that may have been one of the causes of back pain. it takes about six months for it to achieve a solid bony spinal fusion.

Eligibility criteria:
inclusion criteria: * confirmatory imaging study (mri or ct) showing lumbar spinal stenosis at one or more levels (l2 to sacrum) defined as narrowing of the central spinal canal, lateral recesses, or neural foramens due to encroachment on the neural structures by the surrounding bone and soft tissue. exclusion criteria: * patients are not eligible if they have evidence of instability on lateral flexion- extension radiographs, defined as a change of #10° of angulation of adjacent segments by cobb measurement or a change of more than 4 mm of anteroposterior or posteroanterior translation.
effects on health related quality of life among patients with chronic pain by interventional pain management

Conditions: Chronic Pain

Summary: how are the health related quality of life among patients with chronic pain effected by interventional pain managment? hypothesis: health related quality of life can be improved by interventional pain management both among patients with localizable pain focuses and among patients among whom no pain focuses can be found. method: health related quality of life using eq-5d and eq-vas is registered at first visit, at the time of treatment for pain focuses an during the following 12 months.


Eligibility criteria:
inclusion criteria: all patients exclusion criteria: -